51627-47-5Relevant articles and documents
HDAC inhibitor and preparation method and application thereof
-
Paragraph 0272-0273; 0276-0277, (2020/11/12)
The present invention discloses a compound represented by a formula I, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof. The invention further relates to a pharmaceutical composition containing the compound shown in the formula I and application of the compound in preparation of HDAC inhibitor drugs. The compound or the pharmaceutical composition thereof can be used for treating cell proliferation diseases, autoimmune diseases, inflammation, neurodegenerative diseases or viral diseases.
Process for preparing 4-(5-bromine-3-fluoropyridine-2-yl) morpholine
-
Paragraph 0018; 0028; 0038; 0048; 0058; 0065; 0067; 0068, (2018/05/03)
The invention discloses a process for preparing 4-(5-bromine-3-fluoropyridine-2-yl) morpholine. The process comprises the following steps: (1) by taking 2-chlorine-3-nitropyridine as a raw material, performing a substitution reaction so as to generate 4-(3-nitropyridine-2-yl) morpholine; (2) performing a reduction reaction on 4-(3-nitropyridine-2-yl) morpholine to generate 2-morpholino pyridine-3-amine; (3) performing diazotization and substation reactions on 2-morpholino pyridine-3-amine to generate 4-(3-fluorine pyridine-2-yl) morpholine; and (4) performing a substitution reaction on 4-(3-fluorine pyridine-2-yl) morpholine, thereby obtaining a target compound, namely 4-(5-bromine-3-fluoropyridine-2-yl) morpholine. By adopting the process, raw materials are cheap and easy to obtain, operation conditions are gentle and easy to control, products are relatively easy to purify, and practical application can be facilitated.
The synthesis of 3-amino-2-dialkylaminopyridines
Dunn
, p. 709 - 713 (2007/10/03)
-